Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites
T. P. Vassilakopoulos, Gerassimos A. Pangalis(Athens Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Maria Chatziioannou(Laiko General Hospital of Athens), Vassiliki Grigorakis(Laiko General Hospital of Athens), Konstantinos Anargyrou(Laiko General Hospital of Athens), Christos Karkantaris(Laiko General Hospital of Athens), A. Barbounis(Laiko General Hospital of Athens), Marina P. Siakantaris(National and Kapodistrian University of Athens), Maria K. Angelopoulou(Laiko General Hospital of Athens), George Vaiopoulos, Maria Dimopoulou(National and Kapodistrian University of Athens), Flora N. Kontopidou(Laiko General Hospital of Athens), John Rombos(Laiko General Hospital of Athens), Christos Kittas(National and Kapodistrian University of Athens)
Cited by 37
Related Papers
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
|New England Journal of Medicine|2016|1.4k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k
Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
|Science|1993|914
The complex role of tumor-infiltrating macrophages
|Nature Immunology|2022|859